For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass compared ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Semaglutide biosimilar is under clinical development by Leto Laboratories and currently in Phase II for Diabetes.

The study showed diabetic patients taking GLP-1 drugs, such as semaglutide and tirzepatide, faced significantly lower risks of 30-day readmission, wound re-opening and hematoma after surgery, compared ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a ...

Everything you need to know about using Ozempic, Wegovy, and Mounjaro to shed those extra pounds. We dive into their perks, ...